Cerevel Therapeutics Holdings Inc 's ROA from the first quarter of 2024 to the first quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cerevel Therapeutics Holdings Inc 's ROA in the first quarter of 2024?
Cerevel Therapeutics Holdings Inc recorded a cumulative net loss of $-460 million during 12 months ending in the first quarter of 2024, resulting in a negative return on assets (ROA) of -45.91%.

However, within the Healthcare sector 602 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2024 quarter, so far to 4271, from total ROA ranking in the fourth quarter of 2023 at 4907.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter
Y / Y Total Assets Change	26.77 %	22.82 %	-22.43 %	52.01 %	48.38 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-460	-433	-393	-397	-388
Return On Assets (TTM)	-45.91 %	-45.83 %	-44.28 %	-41.94 %	-44.5 %
CERE's Total Ranking	# 4271	# 4907	# 4361	# 4406	# 4592
Total Assets (TTM) in million	1,110	1,225	803	875	876
Seq. Total Assets Change	-9.36 %	52.58 %	-8.21 %	-0.13 %	-12.19 %
Seq. Net Income Change	-	-	-	-	-

CERE's 5 Years Annual ROA >> Back to CERE Management Effectiveness >> Compare CERE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 254
Sector	# 603
Overall	# 4199

Return On Assets Statistics
High	Average	Low
-38.72 %	-84.08 %	-205.52 %
(Nov 30 2012)		(Nov 30 2015)

Financial Statements
Cerevel Therapeutics Holdings Inc 's Assets	$ 1,110 million	CERE's Balance sheet
Cerevel Therapeutics Holdings Inc 's Income	$ -132 million	Quarterly CERE's Income Statement
CERE's Income by Division		See CERE's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Aug 31 2015) FY 2015
Y / Y Total Assets Change	22.82 %	50.43 %	57.49 %	3684.62 %	-65.7 %
Total Assets in million	1,225	997	663	421	11
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-433	-352	-225	-144	-28
Annual Return On Assets	-35.34 %	-35.25 %	-33.99 %	-34.31 %	-253.16 %

CERE's 5 Years Annual ROA >> Back to CERE Management Effectiveness >> Compare CERE ROA to its Competitors

More Return On Assets Ratios
CERE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CERE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CERE's Competitors
Subscribers only: Roa for Cerevel Therapeutics Holdings Inc 's Suppliers
Subscribers only: Return On Assets for CERE's Customers

You may also want to know
CERE's Roi	CERE's Inventory Turnover Ratio	CERE's Growth Rates	CERE's Dividend Comparisons
	CERE's Profitability Ratios	CERE's Asset Turnover Ratio	CERE's Dividend Growth
CERE's Roe	CERE's Valuation Ratios	CERE's Financial Strength Ratios	CERE's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2024, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:24:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.